Clinical Trial Update: INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is assessing whether participants with erythropoietic protoporphyria or X-linked protoporphyria can tolerate more sun exposure without …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythropoietic Protoporphyria
• X-linked Protoporphyria

Drugs mentioned

• Not disclosed

Snippet

Sponsor: Tanabe Pharma America, Inc. | Conditions: Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) | Phase 3 | Status: ACTIVE_NOT_RECRUITING